APA

Lin C., Su W., Yen C., Hsu C., Su W., Yeh K., Lu Y., Cheng A., Huang D. C., Fritsch H., Voss F., Taube T. & Yang J. C. (20140715). A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. : British journal of cancer.

Chicago

Lin C-C, Su W-C, Yen C-J, Hsu C-H, Su W-P, Yeh K-H, Lu Y-S, Cheng A-L, Huang D C-L, Fritsch H, Voss F, Taube T and Yang J C-H. 20140715. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. : British journal of cancer.

Harvard

Lin C., Su W., Yen C., Hsu C., Su W., Yeh K., Lu Y., Cheng A., Huang D. C., Fritsch H., Voss F., Taube T. and Yang J. C. (20140715). A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. : British journal of cancer.

MLA

Lin C-C, Su W-C, Yen C-J, Hsu C-H, Su W-P, Yeh K-H, Lu Y-S, Cheng A-L, Huang D C-L, Fritsch H, Voss F, Taube T and Yang J C-H. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. : British journal of cancer. 20140715.